Chromosomal translocations and secondary leukemias induced by topoisomerase II inhibitors;Translocations chromosomiques et leucemies induites par les medicaments anticancereux inhibiteurs de la topo-isomerase II

Bulletin du Cancer

Volumn 85, Issue 3, 1998, Pages 254-261

  Dassonneville, Laurent ^a   Bailly, Christian ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

Chemotherapy; Chromosomal translocation; Therapy induced leukemia; Topoisomerase II

Indexed keywords

ANTINEOPLASTIC AGENT; BIMOLANE; DNA TOPOISOMERASE INHIBITOR; EPIPODOPHYLLOTOXIN; ETOPOSIDE; RAZOXANE; TENIPOSIDE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); HYBRID PROTEIN; TUMOR PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CHROMOSOME 11; CHROMOSOME 21; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GENE REARRANGEMENT; HUMAN; LEUKEMIA; LEUKEMOGENESIS; ACUTE DISEASE; ACUTE LYMPHOCYTIC LEUKEMIA; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; GENE TRANSLOCATION; GENETICS; MYELOID LEUKEMIA; REVIEW; SECOND CANCER;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 21; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; GENE REARRANGEMENT; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; NEOPLASM PROTEINS; NEOPLASMS, SECOND PRIMARY; RECOMBINANT FUSION PROTEINS; TRANSLOCATION, GENETIC;

EID: 0032013440     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Pedersen-Bjergaard J. Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review. Leukemia Res 1992; 16: 61-5.
2. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersboll J, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993; 7: 1975-86.
3. Imashuku S, Hibi S, Nakajima F, Mitsui T, Yokoyama S, Kojima S, et al. A review of 125 cases to determine the risk of myelodysplasia and leukemia in pediatric neutropenic patients after treatment with recombinant human granulocyte colony-stimulating factor. Blood 1994; 84: 2380-1.
4. Duguet M, Riou JF. De la topologie de l'ADN aux médicaments antibiotiques et anticancéreux. Médecines/Sciences 1994; 10: 962-72.
5. Pui CH, Relling MV, Behm FG, Hancock ML, Boyett JM, Raimondi SC, et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995; 9: 1680-4.
6. Kumar L. Epipodophyllotoxins and secondary leukemia. Lancet 1993; 342: 819-20.
7. Whitlock JA, Greer JP, Lukens JN. Epipodophyllotoxin-related leukemia: identification of a new subset of secondary leukemia. Cancer 1993; 68: 600-4.
8. Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rørth M. Increased risk of myelodysplasia and leukemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991; 338: 359-63.
9. Pedersen-Bjergaard J. Sigsgaard TC, Nielsen D, Gjedde SB, Philip P, Hansen M, et al. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol 1992; 10: 1444-51.
10. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 1994; 91: 1781-5.
11. Bhavnani M, Wolstenholme RJ. Razoxane and acute promyelocytic leukemia. Lancet 1987; II: 1085-7.
12. Xue Y, Lu D, Guo Y, Lin BJ. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. Leukemia Res 1992; 16: 1113.
13. Pedersen-Bjergaard J. The dioxopiperazine derivatives, their leukemogenic potential and other biological effects. Leukemia Res 1992; 16: 1057-9.
14. Bae YS, Kawasaki I, Ikeda H, Liu LF. Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro. Proc Natl Acad Sci USA 1988; 85: 2076-80.
15. Ikeda H, Aoki K, Naito A. Illegitimate recombination mediated in vitro by DNA gyrase of Escherichia coli: structure of recombinant DNA molecules. Proc Natl Acad Sci USA 1982; 79: 3724-8.
16. Lindsley JE. Intradimerically tethered DNA topoisomerase II is catalytically active in DNA transport. Proc Natl Acad Sci USA 1996; 93: 2975-80.
17. Bigioni M, Zunino F, Capranico G. Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage. Nucleic Adels Res 1994; 22:2274-81.
18. Roca J, Wang JC. DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell 1994; 77: 609-16.
19. Nucifora G, Birn DJ, Erickson P, Gao J, Le Beau MM, Drabkin HA, et al. Detection, of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO fusion mRNA with t(8;21) acute myeloid leukemia. Blood 1993; 81: 883-8.
20. Pedersen-Bjergaard J, Johansson B, Philip P. Translocation (3;21)(q26;q22) in therapy-related myelodysplasia following drugs targeting DNA-topoisomerase II combined with alkylating agents, and in myeloproliferative disorders undergoing spontaneous leukemic transformation. Cancer Genet Cytogenet 1994; 76: 50-5.
21. Tigaud I, Tigaud JD, Rimokh R, Samarut C, Magaud JP. Remaniement de la bande chromosomique 11q23 dans les hémopathies malignes. Hématologie 1995; 4: 319-24.
22. Behm FG, Raimondi SC, Frestedt JL, Liu Q, Crist WM, Downing JR, et al. Rearrangement of the MLL gene confers a poor prognosis in chilhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996; 87: 2870-7.
23. Ross JA, Potter JD, Robison LL. Infant leukemia, topoisomerase II inhibitors, and the MLL gene. J Natl Cancer Inst 1994; 86: 1678-80.
24. Ford AM, Ridge SA, Cabrera ME, Mahmoud H, Steel CM, Chan LC, Greaves M. In utero rearrangements in the trithorax-related oncogene in infant leukemias. Nature 1993; 363: 358-60.
25. Chen Z, Tong JH, Dong S, Zhu J, Wang ZY, Chen SJ. Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. Genes Chrom Cancer 1996; 15: 147-56.
26. Rasio D, Schichman SA, Negrini M, Canaani E, Croce CM. Complete exon structure of the ALL1 gene. Cancer Res 1996; 56: 1766-9.
27. Gu Y, Cimino G, Alder H, Nakamura T, Prasad R, Canaani O, et al. The (4;11)(q21;q23) chromosome translocations in acute leukemias involve the VDJ recombinase. Proc Natl Acad Sci USA 1992; 89: 10464-8.
28. Schichman S, Caligiuri M, Strout M, Carter S, Gu Y, Canaani E, et al. ALL-1 tandem duplication in acute leukemia with a normal karyotype involves homologous recombination between Alu elements. Cancer Res 1994; 54: 4277-80.
29. Domer PH, Fakharzadeh SS, Chen CS, Jockel J, Johansen L, Silverman GA, et al. Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product. Proc Natl Acad Sci USA 1993; 90: 7884-8.
30. Krowczynska AM, Rudders RA, Krontiris TG. The human minisatellite consensus at breakpoints of oncogene translocations. Nucleic Acids Res 1990; 18: 1121-7.
31. Pommier Y, Bertrand R. The mechanisms of formation of chromosomal aberrations: role of eukaryotic DNA topoisomerases. In: Kirsch IR, ed. The causes and consequences of chromosomal aberrations. London: CRC Press, 1993, pp. 277-309.
32. Domer PH, Head DR, Renganathan N, Raimondi SC, Yang E, Atlas M. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia the t(4;11). Leukemia 1995; 9: 1305-12.
33. Felix CA, Lange BJ, Hosler MR, Fertala J, Bjornsti MA. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res 1995; 55: 4287-92.
34. Aplan PD, Chervinsky DS, Stanulla M, Burhans WC. Site-specific DNA cleavage within the MZi breakpoint cluster region induced by topoisomerase II inhibitors. Blood 1996; 87: 2649-58.
35. Stanulla M, Wang J, Chervinsky DS, Thandla S, Aplan PD. DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis. Mol Cell Biol 1997; 17: 4070-9.
36. Spitzner JR, Muller MT. A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acids Res 1988; 16: 5533-56.
37. Sander M, Hsieh T. Drosophila topoisomerase II double strand DNA cleavage: analysis of DNA sequence homology at the cleavage site. Nucleic Acids Res 1985; 13: 1057-72.
38. Käs E, Laemmli UK. In vivo topoisomerase II cleavage of Drosophila histone and satellite III repeats: DNA sequence and structural characteristics. EMBO J 1992; 11: 705-16.
39. Bernard OA, Mauchauffe M, Mecucci C, Van den Berghe H, Berger R. A novel gene, AF-1p, fused to HRX in t(1;11)(p32;q23), is not related to AF-4, AF-9 nor ENL. Oncogene 1994; 9: 1039-45.
40. Tse W, Zhu W, Chen HS, Cohen A. A novel gene, AF1q, fused to MLL in t(1;11)(q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. Blood 1995; 85: 650-6.
41. Gu Y, Nakamura T, Alder H, Prasad R, Canaani O, Cimino G, Croce CM, Canaani E. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 1992; 71: 701-8.
42. Taki T, Hayashi Y, Taniwaki M, Seto M, Ueda R, Hanada R, et al. Fusion of the MLL gene with two different genes, AF-6 and AF-5a, by a complex translocation involving chromosomes 5, 6, 8 and 11 in infant leukemia. Oncogene 1996; 13: 2121-30.
43. Prasad R, Gu Y, Alder H, Nakamura T, Canaani O, Saito H, et al. Cloning of the ALL-1 fusion partner, the AF-6 gene, involved in acute myeloid leukemia with the t(6;11) chromosome translocation. Cancer Res 1993; 53: 5624-8.
44. Iida S, Seto M, Yamamoto K, Komatsu H, Tojo A, Asano S, et al. MLLT3 gene on 9p22 involved in t(9;11) leukemia encodes a serine/proline rich protein homologous to MLLT1 on 19p13. Oncogene 1993; 8: 3085-92.
45. Chaplin T, Berbard O, Beverloo HB, Saha V, Hagemeijer A, Berger R. et al. The t(10;11) translocation in acute myeloid leukemia (M5) consistently fuses the leucine zipper motif of AF10 onto the HRX gene. Blood 1995; 86: 2073-6.
46. Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, et al. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci USA 1997; 94: 8732-7.
47. Prasad R, Leshkowitz D, Gu Y, Alder H, Nakamura T, Saito H, et al. Leucine zipper dimerization motif encoded by the AF-17 gene fuse to ALL-1 (MLL) in acute leukemia. Proc Natl Acad Sci USA 1994; 91: 8107-11.
48. Tkachuk DC, Kohler S, Clearly ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992; 71: 691-700.
49. Thirman MJ, Levitan DA, Kobayashi H, Simon MC, Rowley JD. Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia. Proc Natl Acad Sci USA 1994; 91: 12110-4.
50. Borkhardt A, Repp R, Haas OA, Leis T, Harbott J, Kreuder J, et al. Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23). Oncogene 1997; 14: 195-202.